Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2025)

Historic Current Leases for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $981000.0.

  • Amylyx Pharmaceuticals' Current Leases fell 5025.35% to $981000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $981000.0, marking a year-over-year decrease of 5025.35%. This contributed to the annual value of $1.5 million for FY2024, which is 3274.26% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Current Leases stood at $981000.0, which was down 5025.35% from $665000.0 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Current Leases ranged from a high of $2.4 million in Q2 2024 and a low of $665000.0 during Q2 2025
  • For the 4-year period, Amylyx Pharmaceuticals' Current Leases averaged around $1.8 million, with its median value being $2.0 million (2022).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Current Leases skyrocketed by 4896.8% in 2023 and then crashed by 7192.91% in 2025.
  • Amylyx Pharmaceuticals' Current Leases (Quarter) stood at $2.0 million in 2022, then grew by 10.64% to $2.3 million in 2023, then crashed by 32.74% to $1.5 million in 2024, then tumbled by 35.38% to $981000.0 in 2025.
  • Its Current Leases was $981000.0 in Q3 2025, compared to $665000.0 in Q2 2025 and $1.1 million in Q1 2025.